Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
Phase 2
Completed
NCT03573024
| Condition | Acute Myeloid Leukemia |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Colorado, Denver |
|---|
| Status | Completed |
|---|
| Enrollment | 36 participants |
|---|
| Interventions | Azacitidine, Venetoclax |
|---|
| Start date | Nov 28, 2018 |
|---|
| Completion date | Apr 14, 2025 |
|---|
| Results posted | Jun 11, 2026 |
|---|
Summary
This study aims to treat non-elderly adult patients, who were previously untreated for acute myeloid leukemia, using venetoclax and azacitidine.
Response Rate, Measured by the European Leukemia Net Definition: (CRMRD-+CR+CRi+MLFS)
Study start date to study end date, or death, whichever comes first, approximately 4 years · Participants
| Azacitidine and Venetoclax | 25 Participants |
|---|
Number of Participants That Achieved Minimal Residual Disease (MRD) Negative Responses
Study start date to study end date, or death, whichever comes first, approximately 4 years · Participants
| Azacitidine and Venetoclax | 23 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.